Xlifesc, Ltd.

11 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2036

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 11, 2026
The maintenance fee for Soluble and stable heterodimeric TCR (US 10,316,087) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
1 fee due Jun 26, 2027
The maintenance fee for Soluble heterodimeric T cell receptor, and preparation method and use thereof (US 11,851,469) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,316,087	Soluble and stable heterodimeric TCR In force Term ends Mar 29, 2036 · From the USPTO record	In force	Term ends Mar 29, 2036	From the USPTO record
US 11,851,469	Soluble heterodimeric T cell receptor, and preparation method and use thereof In force Term ends Mar 28, 2039 · From the USPTO record	In force	Term ends Mar 28, 2039	From the USPTO record
US 11,649,270	T-Cell Receptor Recognizing SSX2 Antigen In force Term ends Oct 25, 2039 · High confidence	In force	Term ends Oct 25, 2039	High confidence
US 12,344,652	High-affinity TCR for NY-ESO In force Term ends Jan 15, 2040 · From the USPTO record	In force	Term ends Jan 15, 2040	From the USPTO record
US 12,662,522	High-Affinity TCR for Recognizing SSX2 Antigen In force Term ends Jan 24, 2041 · High confidence	In force	Term ends Jan 24, 2041	High confidence
US 12,275,773	High Affinity Cell Receptor for Recognizing Afp Antigen In force Term ends Jan 20, 2042 · High confidence	In force	Term ends Jan 20, 2042	High confidence
US 12,152,065	T cell receptor for identifying AFP antigen In force Term ends Mar 29, 2042 · From the USPTO record	In force	Term ends Mar 29, 2042	From the USPTO record
US 12,649,773	T Cell Receptor for Recognizing SSX2 Antigen Short Peptide In force Term ends Jun 29, 2042 · High confidence	In force	Term ends Jun 29, 2042	High confidence
US 12,522,643	High-Affinity TCR for Afp Recognition In force Term ends Mar 29, 2043 · High confidence	In force	Term ends Mar 29, 2043	High confidence
US 12,570,713	High-Affinity TCR for Recognizing AFP Antigen In force Term ends Apr 9, 2043 · High confidence	In force	Term ends Apr 9, 2043	High confidence

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Also on record, not counted in the 11: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 2 abandoned · 1 no status recorded

List them